
|Articles|May 15, 2003
Cyclosporine offers new approach to dry eye treatment
Author(s)Lynda Charters
Maui, HI-FDA approval of Restasis (cyclosporine ophthalmic emulsion, 0.05%, Allergan, Irvine, CA), in December opened a new door for patients with dry eye disease by offering two important "firsts": the drug provides more than palliation of dry eye symptoms, and it targets the inflammation that is the underlying cause of dry eye disease. It may even effect a cure in some patients. The drug became commercially available early last month.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Evolving glaucoma therapy: A new era of interventional strategies
2
ICYMI: AAO 2025 showcases new technologies and continued research
3
Precision strategy: Optimizing visual outcomes with advanced small-aperture lenses
4
Throwback Series: Managing bilateral diabetic macular edema early in practice
5

















































.png)


